Spots Global Cancer Trial Database for solid tumors
Every month we try and update this database with for solid tumors cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Trial of Two Schedules of Perifosine for Patients With Solid Tumors or Lymphomas | NCT00389077 | Tumors Lymphomas | Perifosine | 18 Years - | AEterna Zentaris | |
| Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies | NCT05707325 | Cancer Solid Tumor Hematologic Mal... | engineered red ... | 18 Years - 75 Years | Westlake Therapeutics | |
| Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | NCT04198766 | Solid Tumor Non-Small Cell ... Melanoma Head and Neck C... Gastric Cancer Renal Cell Carc... Urothelial Carc... | INBRX-106 - Hex... Pembrolizumab 2... Pembrolizumab 4... | 18 Years - | Inhibrx, Inc. | |
| Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors | NCT05957471 | Locally Advance... | Drug: BC3195 fo... | 18 Years - | Biocity Biopharmaceutics Co., Ltd. | |
| Study of INCB123667 in Subjects With Advanced Solid Tumors | NCT05238922 | Solid Tumors | INCB0123667 | 18 Years - | Incyte Corporation | |
| Phase 1 Trial of Intravenously Administered Nerofe™ in Subjects With Advanced Malignancies | NCT01690741 | Cancer | Nerofe | 18 Years - | Immune System Key Ltd | |
| Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer | NCT01538563 | Solid Tumors Advanced Cancer Cancer Neoplasms | rigosertib sodi... | 18 Years - | Traws Pharma, Inc. | |
| A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | NCT05668585 | Solid Tumors Melanoma NSCLC CRC ATC | CFT1946 Trametinib Cetuximab | 18 Years - | C4 Therapeutics, Inc. | |
| This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas | NCT02171260 | Pediatrics Solid Tumors | Eribulin Mesyla... | 6 Months - 17 Years | Eisai Inc. | |
| A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors | NCT04941339 | Advanced Solid ... | MRG002 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| Allogeneic Hematopoietic Stem Cell Transplantation | NCT00750126 | Solid Tumors Hematologic Neo... | Fludarabine, Bu... | - 20 Years | University Hospital, Clermont-Ferrand | |
| Hepatic Arterial Infusion (HAI) of Abraxane | NCT00732836 | Liver Cancer Advanced Cancer... Solid Tumors | HAI Abraxane Hepatic Artery ... IV Abraxane | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax). | NCT01021358 | Lymphoma Chronic Lymphoc... Solid Tumors | ABT-263 Ketoconazole | 18 Years - | Abbott | |
| Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas | NCT02740270 | Solid Tumors Lymphomas | GWN323 PDR001 | 18 Years - | Novartis | |
| Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors | NCT01454804 | Advanced Cancer... | Pazopanib Lapatinib Trastuzumab (He... Pazopanib | - | M.D. Anderson Cancer Center | |
| Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases | NCT05477927 | Malignant Perit... Malignant Ascit... Serous Cavity M... | Dual-targeting ... | 18 Years - 65 Years | Sichuan University | |
| PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors | NCT02022982 | KRAS Mutant Non... Solid Tumors | Palbociclib PD-0325901 | 18 Years - | Dana-Farber Cancer Institute | |
| A Research Study to Evaluate the Safety of R306465, a Drug in Development for Cancer and to Study the Absorption, Break Down and Elimination in Patients With Advanced Solid Malignancies. | NCT00677001 | Neoplasms | R306465 | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate | NCT01844869 | Hematologic Mal... Solid Tumors | omacetaxine mep... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors | NCT03252938 | Solid Tumors Peritoneal Carc... | IMP321 Avelumab | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors | NCT01999738 | Solid Tumors Non Small Cell ... | EC1456 and EC20 | 18 Years - | Endocyte | |
| An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors | NCT00514267 | Prostate Cancer Tumors | YM 155 Docetaxel Prednisone | 18 Years - | Astellas Pharma Inc | |
| Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors | NCT00636545 | Solid Tumors | Oblimersen (Gen... Oblimersen (Gen... | 18 Years - | Genta Incorporated | |
| Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors | NCT01166035 | Solid Tumors | Lenalidomide Cetuximab | 18 Years - 80 Years | Medical University Innsbruck | |
| Whey Protein Supplementation in Cancer Patients | NCT02065726 | Solid Tumors | Whey protein Nutritional cou... | 18 Years - | IRCCS Policlinico S. Matteo | |
| One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy | NCT00358397 | Tumors | Clostridium nov... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors | NCT01176500 | Colon Cancer Lung Cancer Cervical Cancer Renal Cell Carc... Uterine Cancer | (18)Fluciclatid... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001 | NCT03292783 | Advanced Solid ... | NOV1501 (ABL001... | 19 Years - | ABL Bio, Inc. | |
| Phase I Study of Intravenous Artesunate for Solid Tumors | NCT02353026 | Solid Tumors | Intravenous Art... | 18 Years - | Georgetown University | |
| A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors | NCT00744562 | Solid Tumors | OMP-21M18 | 21 Years - | Mereo BioPharma | |
| Dose Escalation Study of NKP-1339 to Treat Advanced Solid Tumors | NCT01415297 | Solid Tumors | NKP-1339 | 18 Years - | Intezyne Technologies, Inc. | |
| Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650) | NCT01463696 | Solid Tumors | MK-8242 | 18 Years - | Merck Sharp & Dohme LLC | |
| Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients With CLDN18.2-positive Advanced Solid Tumors | NCT06084286 | Advanced Solid ... | Dual-targeting ... | 18 Years - 75 Years | Sichuan University | |
| Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients | NCT00500422 | Solid Tumors | Doxil Gemcitabine Velcade | - | M.D. Anderson Cancer Center | |
| Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas | NCT00553189 | Solid Tumors Lymphomas | ABT-888 Topotecan | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| An Open Label Treatment Extension Study of AMG 706 | NCT00360867 | Solid Tumors | AMG 706 | 18 Years - | Amgen | |
| Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies | NCT01461538 | Acute Lymphoid ... Acute Myeloid L... Anemia, Refract... Solid Tumors | brentuximab ved... brentuximab ved... brentuximab ved... | 6 Years - | Seagen Inc. | |
| Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors | NCT00424632 | Solid Tumors | PF-03814735 | 18 Years - | Pfizer | |
| A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML | NCT03690154 | Advanced Cancer Solid Tumors Acute Myeloid L... Acute Myeloid L... | FN-1501 | 18 Years - | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | |
| Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors | NCT01049893 | Solid Tumors | Compound AC220 | 18 Years - | Daiichi Sankyo | |
| A Study of IBI363 in Subjects With Advanced Solid Malignancies | NCT06281678 | Solid Tumors | IBI363 | 18 Years - | Innovent Biologics (Suzhou) Co. Ltd. | |
| CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | NCT02675946 | Solid Tumors GI Cancer | CGX1321 Pembrolizumab encorafenib cetuximab | 18 Years - | Curegenix Inc. | |
| A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors | NCT04857138 | Solid Tumors | RO7300490 Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma | NCT02269943 | Nasopharyngeal ... | CC-486 | 18 Years - | Celgene | |
| A Phase I Trial of ZIO-101 in Solid Tumors | NCT00591396 | Solid Tumors | ZIO-101 (Darina... | - | Alaunos Therapeutics | |
| Karenitecin in Pediatric Patients With Refractory or Recurrent Solid Tumors N10010) | NCT00586560 | Solid Tumors | Kareniticin and... | 12 Months - 21 Years | Baylor College of Medicine | |
| Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | NCT06065059 | Breast Cancer Ovarian Cancer Pancreas Cancer Prostate Cancer BRCA1 Mutation BRCA-Mutated Ov... BRCA-Associated... HRD Positive Ad... | TNG348 Olaparib | 18 Years - | Tango Therapeutics, Inc. | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors | NCT04843709 | Advanced or Met... | MRG004A | 18 Years - | Shanghai Miracogen Inc. | |
| Pharmacokinetics Study of Nimotuzumab in Patients With Solid Tumors | NCT02395068 | Solid Tumors | Nimotuzumab irinotecan | 18 Years - 70 Years | Biotech Pharmaceutical Co., Ltd. | |
| Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors | NCT01862328 | Solid Tumors | MLN4924 Paclitaxel Gemcitabine Docetaxel Carboplatin | 18 Years - | Takeda | |
| Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors | NCT01544322 | Solid Tumors | ME-344 | 18 Years - | MEI Pharma, Inc. | |
| Study of KRN951 in Patients With Solid Tumors | NCT00970411 | Solid Tumors | KRN951 | 20 Years - | Kyowa Kirin Co., Ltd. | |
| Study of JS001 in Participants With Advanced Solid Tumors | NCT02857166 | Solid Tumors | humanized anti-... | 18 Years - 75 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy | NCT03616834 | Solid Tumors | Tomivosertib (e... | 18 Years - | Effector Therapeutics | |
| Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors | NCT01283945 | Solid Tumors | Lucitanib | 18 Years - | Servier | |
| Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma | NCT00322608 | Cancer | NPI-2358 | 18 Years - | Nereus Pharmaceuticals, Inc. | |
| A Study of CriPec® Docetaxel Given to Patients With Solid Tumours | NCT02442531 | Cancer Metastatic Canc... Solid Tumors | CriPec® docetax... | 18 Years - | Cristal Therapeutics | |
| Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients | NCT00500422 | Solid Tumors | Doxil Gemcitabine Velcade | - | M.D. Anderson Cancer Center | |
| QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas | NCT01231347 | Adenocarcinoma ... Advanced Solid ... Cancer Cancer of Pancr... Cancer of the P... Metastases Metastatic Canc... Metastatic Panc... Pancreas Cancer Pancreatic Canc... Bone Metastases Endocrine Cance... Oncology Oncology Patien... Solid Tumors Advanced Malign... | AMG 479 Placebo AMG 479 gemcitabine | 18 Years - | NantCell, Inc. | |
| A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors | NCT00842335 | Advanced Solid ... | JI-101 | 18 Years - | Jubilant Innovation Ltd. | |
| A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors | NCT00743067 | Solid Tumours | GSK1363089 (for... | 18 Years - | GlaxoSmithKline | |
| Epidemiology of Diarrheal Diseases in Pediatric Oncology Patients | NCT02464098 | Diarrhea | - 18 Years | St. Jude Children's Research Hospital | ||
| Personalized Cellular Vaccine for Brain Metastases (PERCELLVAC3) | NCT02808416 | Brain Cancer Neoplasm Metast... | Personalized ce... | 18 Years - 65 Years | Guangdong 999 Brain Hospital | |
| A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC | NCT01957007 | Solid Tumors | Docetaxel vantictumab | 18 Years - 90 Years | Mereo BioPharma | |
| Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor | NCT01212341 | Malignant Lymph... Solid Tumors | Allogeneic NK c... | 18 Years - | Seoul National University Hospital | |
| Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder | NCT05512377 | Pancreatic Neop... Solid Tumors Biliary Tract C... Lung Neoplasms Bladder Cancer | brigimadlin | 18 Years - | Boehringer Ingelheim | |
| Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma | NCT00413075 | Solid Tumor Lymphoma | oral belinostat | 18 Years - | Valerio Therapeutics | |
| Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors | NCT01357330 | Solid Tumors | SAR245408 (XL14... MSC1936369B | 18 Years - | Sanofi | |
| Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors | NCT00977210 | Solid Tumors | OXi4503 | 18 Years - | Mateon Therapeutics | |
| Biomarker Development for Response Prediction by DNA Mutational Analysis | NCT01855061 | Neoplasm Metast... | Biopsy Blood samples Pharmacokinetic... Midazolam clear... | 18 Years - | UMC Utrecht | |
| Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors | NCT00776867 | Solid Tumors | perifosine | - 21 Years | Memorial Sloan Kettering Cancer Center | |
| A Study of DF6002 Alone and in Combination With Nivolumab | NCT04423029 | Solid Tumors | DF6002 Nivolumab | 18 Years - | Dragonfly Therapeutics | |
| Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R | NCT02045368 | Breast Cancer Brain Cancer Gastrointestina... Genitourinary C... Gynecologic Can... Head and Neck C... Melanoma Thoracic Cancer... | IGF-Methotrexat... | 18 Years - | IGF Oncology, LLC | |
| Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours | NCT02042781 | Advanced Solid ... | PG545 | 18 Years - | Zucero Pty Ltd | |
| Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer | NCT01423903 | Advanced Cancer | OPB-51602 | 18 Years - | Otsuka Pharmaceutical Development & Commercialization, Inc. | |
| Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors | NCT00730470 | Advanced Solid ... | U3-1287 (AMG888... | 18 Years - | U3 Pharma GmbH | |
| Study of PX-866 and Docetaxel in Solid Tumors | NCT01204099 | Non Small Cell ... Squamous Cell C... | Docetaxel PX-866 | 18 Years - | Seagen Inc. | |
| Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors | NCT01324479 | Solid Tumors | INC280 | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
